{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:06:57Z","timestamp":1794668817025,"version":"4.9.1"},"reference-count":140,"publisher":"Elsevier","isbn-type":[{"value":"9780323853019","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.pmbts.2021.01.029","type":"book-chapter","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T10:33:32Z","timestamp":1615113212000},"page":"225-255","source":"Crossref","is-referenced-by-count":9,"title":["Gene editing and modulation for Duchenne muscular dystrophy"],"prefix":"10.1016","author":[{"given":"Anthony A.","family":"Stephenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","article-title":"Duchenne and Becker muscular dystrophies","volume":"32","author":"Flanigan","year":"2014","journal-title":"Neurol Clin"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JND-170280","article-title":"Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database","volume":"4","author":"Koeks","year":"2017","journal-title":"J Neuromuscul Dis"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2021.01.029_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/mgme.2001.3220","article-title":"Dystrophin and muscular dystrophy: past, present, and future","volume":"74","author":"O'Brien","year":"2001","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng0493-283","article-title":"The structural and functional diversity of dystrophin","volume":"3","author":"Ahn","year":"1993","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"issue":"8","key":"10.1016\/bs.pmbts.2021.01.029_bb0035","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/nar\/11.8.2303","article-title":"Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular dystrophy locus on the short arm of the human X chromosome","volume":"11","author":"Davies","year":"1983","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/bs.pmbts.2021.01.029_bb0040","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/jmg.23.6.484","article-title":"Muscular dystrophy in girls with X; autosome translocations","volume":"23","author":"Boyd","year":"1986","journal-title":"J Med Genet"},{"issue":"7","key":"10.1016\/bs.pmbts.2021.01.029_bb0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/hmg\/1.7.505","article-title":"Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters","volume":"1","author":"Gorecki","year":"1992","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF02265272","article-title":"Expression and regulation of the dystrophin Purkinje promoter in human skeletal muscle, heart, and brain","volume":"97","author":"Holder","year":"1996","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0055","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1073\/pnas.88.4.1276","article-title":"Dystrophin is transcribed in brain from a distant upstream promoter","volume":"88","author":"Boyce","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1440-1681.2007.04816.x","article-title":"GABA(A) receptor expression and inhibitory post-synaptic currents in cerebellar Purkinje cells in dystrophin-deficient mdx mice","volume":"35","author":"Kueh","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.nlm.2013.10.017","article-title":"Regional and genotypic differences in intrinsic electrophysiological properties of cerebellar Purkinje neurons from wild-type and dystrophin-deficient mdx mice","volume":"107","author":"Snow","year":"2014","journal-title":"Neurobiol Learn Mem"},{"issue":"5","key":"10.1016\/bs.pmbts.2021.01.029_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/hmg\/4.5.837","article-title":"A novel dystrophin isoform is required for normal retinal electrophysiology","volume":"4","author":"Dsouza","year":"1995","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/bs.pmbts.2021.01.029_bb0075","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1073\/pnas.89.12.5346","article-title":"A 71-kilodalton protein is a major product of the Duchenne muscular-dystrophy gene in brain and other nonmuscle tissues","volume":"89","author":"Lederfein","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0080","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/hmg\/4.9.1475","article-title":"Cloning and characterization of alternatively spliced isoforms of Dp71","volume":"4","author":"Austin","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12981-5","article-title":"Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy","volume":"7","author":"Doorenweerd","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/ng0593-77","article-title":"An alternative dystrophin transcript specific to peripheral nerve","volume":"4","author":"Byers","year":"1993","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/hmg\/4.3.329","article-title":"Dp140\u2014a novel 140-Kda Cns transcript from the Dystrophin locus","volume":"4","author":"Lidov","year":"1995","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ng0593-82","article-title":"Dystrophin expression in the human retina is required for normal function as defined by electroretinography","volume":"4","author":"Pillers","year":"1993","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0306-4522(96)00069-3","article-title":"Dystrophin and the dystrophin-associated glycoprotein, beta-dystroglycan, co-localize in photoreceptor synaptic complexes of the human retina","volume":"73","author":"Drenckhahn","year":"1996","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/bs.pmbts.2021.01.029_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.tins.2012.04.004","article-title":"The dystrophin-glycoprotein complex in brain development and disease","volume":"35","author":"Waite","year":"2012","journal-title":"Trends Neurosci"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12035-012-8233-5","article-title":"The shortest isoform of dystrophin (Dp40) interacts with a group of presynaptic proteins to form a presumptive novel complex in the mouse brain","volume":"45","author":"Tozawa","year":"2012","journal-title":"Mol Neurobiol"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0120","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm.3628","article-title":"Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice","volume":"20","author":"Wein","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2478\/bjmg-2013-0014","article-title":"Association between loss of dp140 and cognitive impairment in duchenne and Becker dystrophies","volume":"16","author":"Chamova","year":"2013","journal-title":"Balkan J Med Genet"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/WNL.55.4.559","article-title":"Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy","volume":"55","author":"Felisari","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0960-8966(99)00108-X","article-title":"Loss of Dp140 regulatory sequences is associated with cognitive impairment in dystrophinopathies","volume":"10","author":"Bardoni","year":"2000","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1083\/jcb.122.4.809","article-title":"A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin","volume":"122","author":"Ervasti","year":"1993","journal-title":"J Cell Biol"},{"issue":"18","key":"10.1016\/bs.pmbts.2021.01.029_bb0145","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1074\/jbc.M117.809798","article-title":"Dystrophin's central domain forms a complex filament that becomes disorganized by in-frame deletions","volume":"293","author":"Delalande","year":"2018","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","article-title":"The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein","volume":"53","author":"Koenig","year":"1988","journal-title":"Cell"},{"issue":"8","key":"10.1016\/bs.pmbts.2021.01.029_bb0155","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/S0021-9258(19)39599-7","article-title":"Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility","volume":"265","author":"Koenig","year":"1990","journal-title":"J Biol Chem"},{"issue":"43","key":"10.1016\/bs.pmbts.2021.01.029_bb0160","doi-asserted-by":"crossref","first-page":"28419","DOI":"10.1074\/jbc.273.43.28419","article-title":"A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction","volume":"273","author":"Amann","year":"1998","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0165","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1083\/jcb.200905048","article-title":"Dystrophin is a microtubule-associated protein","volume":"186","author":"Prins","year":"2009","journal-title":"J Cell Biol"},{"issue":"15","key":"10.1016\/bs.pmbts.2021.01.029_bb0170","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1073\/pnas.1323842111","article-title":"Microtubule binding distinguishes dystrophin from utrophin","volume":"111","author":"Belanto","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI36612","article-title":"Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy","volume":"119","author":"Lai","year":"2009","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0180","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1515\/BC.1999.057","article-title":"The WW domain of dystrophin requires EF-hands region to interact with beta-dystroglycan","volume":"380","author":"Rentschler","year":"1999","journal-title":"Biol Chem"},{"issue":"23","key":"10.1016\/bs.pmbts.2021.01.029_bb0185","doi-asserted-by":"crossref","first-page":"12413","DOI":"10.1073\/pnas.94.23.12413","article-title":"Dystrobrevin and dystrophin: an interaction through coiled-coil motifs","volume":"94","author":"Sadoulet-Puccio","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.128.3.373","article-title":"Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus","volume":"128","author":"Suzuki","year":"1995","journal-title":"J Cell Biol"},{"issue":"6254","key":"10.1016\/bs.pmbts.2021.01.029_bb0195","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0200","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.omtm.2017.06.006","article-title":"A five-repeat micro-Dystrophin gene ameliorated dystrophic phenotype in the severe DBA\/2J-mdx model of Duchenne muscular dystrophy","volume":"6","author":"Hakim","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"25","key":"10.1016\/bs.pmbts.2021.01.029_bb0210","doi-asserted-by":"crossref","first-page":"13714","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11\u221212","key":"10.1016\/bs.pmbts.2021.01.029_bb0215","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.nmd.2007.07.005","article-title":"Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human","volume":"17","author":"Neri","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"Pt. 12","key":"10.1016\/bs.pmbts.2021.01.029_bb0220","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/brain\/awr291","article-title":"Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials","volume":"134","author":"Anthony","year":"2011","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0225","first-page":"54","article-title":"Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies","volume":"49","author":"Beggs","year":"1991","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/bs.pmbts.2021.01.029_bb0230","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","article-title":"Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort","volume":"30","author":"Flanigan","year":"2009","journal-title":"Hum Mutat"},{"issue":"15","key":"10.1016\/bs.pmbts.2021.01.029_bb0235","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","article-title":"Developing standardized corticosteroid treatment for Duchenne muscular dystrophy","volume":"58","author":"Guglieri","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0245","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0250","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajmg.a.30617","article-title":"Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort","volume":"134","author":"Dent","year":"2005","journal-title":"Am J Med Genet A"},{"issue":"21","key":"10.1016\/bs.pmbts.2021.01.029_bb0255","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJM198805263182104","article-title":"Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy","volume":"318","author":"Hoffman","year":"1988","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0260","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/humu.20913","article-title":"DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6","volume":"30","author":"Gurvich","year":"2009","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/bs.pmbts.2021.01.029_bb0265","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.nmd.2009.08.010","article-title":"DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy","volume":"19","author":"Flanigan","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0270","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.nmd.2017.11.007","article-title":"Low-level dystrophin expression attenuating the dystrophinopathy phenotype","volume":"28","author":"Waldrop","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2014.01.009","article-title":"Low dystrophin levels in heart can delay heart failure in mdx mice","volume":"69","author":"van Putten","year":"2014","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0280","doi-asserted-by":"crossref","first-page":"a017285","DOI":"10.1101\/cshperspect.a017285","article-title":"The status of RPE65 gene therapy trials: safety and efficacy","volume":"5","author":"Pierce","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0285","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0290","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0295","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0300","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/01.RES.0000237661.18885.f6","article-title":"Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo","volume":"99","author":"Pacak","year":"2006","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0305","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/17425247.2014.871258","article-title":"The potential of adeno-associated viral vectors for gene delivery to muscle tissue","volume":"11","author":"Wang","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"10.1016\/bs.pmbts.2021.01.029_bb0310","first-page":"3148","article-title":"Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector [in Japanese]","volume":"55","author":"Yuasa","year":"1997","journal-title":"Nihon Rinsho"},{"issue":"12","key":"10.1016\/bs.pmbts.2021.01.029_bb0315","first-page":"1154","article-title":"Development of new therapy on muscular dystrophy [in Japanese]","volume":"41","author":"Takeda","year":"2001","journal-title":"Rinsho Shinkeigaku"},{"issue":"10","key":"10.1016\/bs.pmbts.2021.01.029_bb0320","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/bs.pmbts.2021.01.029_bb0325","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCGENETICS.109.867242","article-title":"Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy","volume":"2","author":"Kaspar","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"6","key":"10.1016\/bs.pmbts.2021.01.029_bb0330","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.bbapap.2009.02.016","article-title":"Differential stabilities of alternative exon-skipped rod motifs of dystrophin","volume":"1794","author":"Ruszczak","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0335","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The Dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0340","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"issue":"26","key":"10.1016\/bs.pmbts.2021.01.029_bb0345","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0350","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/bs.pmbts.2021.01.029_bb0355","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0360","series-title":"Package Insert","author":"EXONDYS 51","year":"2020"},{"issue":"21","key":"10.1016\/bs.pmbts.2021.01.029_bb0365","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/bs.pmbts.2021.01.029_bb0370","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0375","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0380","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JND-200483","article-title":"Clinical phenotypes of DMD exon 51 skip equivalent deletions: a systematic review","volume":"7","author":"Waldrop","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0385","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1073\/pnas.81.4.1057","article-title":"3\u2032 editing of mRNAs: sequence requirements and involvement of a 60-nucleotide RNA in maturation of histone mRNA precursors","volume":"81","author":"Birchmeier","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/bs.pmbts.2021.01.029_bb0390","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.88.21.9784","article-title":"Two-step affinity purification of U7 small nuclear ribonucleoprotein particles using complementary biotinylated 2'-O-methyl oligoribonucleotides","volume":"88","author":"Smith","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/bs.pmbts.2021.01.029_bb0395","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1101\/gad.274403","article-title":"Unique Sm core structure of U7 snRNPs: assembly by a specialized SMN complex and the role of a new component, Lsm11, in histone RNA processing","volume":"17","author":"Pillai","year":"2003","journal-title":"Genes Dev"},{"issue":"16","key":"10.1016\/bs.pmbts.2021.01.029_bb0400","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1093\/nar\/23.16.3141","article-title":"Assembly, nuclear import and function of U7 Snrnps studied by microinjection of synthetic U7 Rna into xenopus oocytes","volume":"23","author":"Stefanovic","year":"1995","journal-title":"Nucleic Acids Res"},{"issue":"19\u201320","key":"10.1016\/bs.pmbts.2021.01.029_bb0405","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1007\/s00018-004-4190-0","article-title":"The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein","volume":"61","author":"Schumperli","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0410","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/j.1460-2075.1993.tb05764.x","article-title":"The low abundance of U7 Snrna is partly determined by its Sm binding-site","volume":"12","author":"Grimm","year":"1993","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0415","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1073\/pnas.95.9.4929","article-title":"Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs","volume":"95","author":"Gorman","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"10.1016\/bs.pmbts.2021.01.029_bb0420","doi-asserted-by":"crossref","first-page":"9456","DOI":"10.1073\/pnas.142302299","article-title":"Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells","volume":"99","author":"De Angelis","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0425","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s000180300047","article-title":"U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping","volume":"60","author":"Brun","year":"2003","journal-title":"Cell Mol Life Sci"},{"issue":"5702","key":"10.1016\/bs.pmbts.2021.01.029_bb0430","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0435","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0888-7543(92)90210-J","article-title":"An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy","volume":"13","author":"Sharp","year":"1992","journal-title":"Genomics"},{"issue":"11","key":"10.1016\/bs.pmbts.2021.01.029_bb0440","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1038\/mt.2012.181","article-title":"Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping","volume":"20","author":"Vulin","year":"2012","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/bs.pmbts.2021.01.029_bb0445","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/14712598.2015.1035645","article-title":"Strategies to circumvent humoral immunity to adeno-associated viral vectors","volume":"15","author":"Tse","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-biochem-060713-035418","article-title":"Genome engineering with targetable nucleases","volume":"83","author":"Carroll","year":"2014","journal-title":"Annu Rev Biochem"},{"issue":"6096","key":"10.1016\/bs.pmbts.2021.01.029_bb0455","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0460","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"elife"},{"issue":"6121","key":"10.1016\/bs.pmbts.2021.01.029_bb0465","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"issue":"11","key":"10.1016\/bs.pmbts.2021.01.029_bb0470","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0475","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1038\/ncomms7244","article-title":"Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy","volume":"6","author":"Ousterout","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0480","first-page":"9","article-title":"Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene","volume":"34","author":"Taglia","year":"2015","journal-title":"Acta Myol"},{"issue":"6271","key":"10.1016\/bs.pmbts.2021.01.029_bb0485","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"issue":"6271","key":"10.1016\/bs.pmbts.2021.01.029_bb0490","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"issue":"6271","key":"10.1016\/bs.pmbts.2021.01.029_bb0495","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0500","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"Creation of a novel humanized dystrophic mouse model of Duchenne muscular dystrophy and application of a CRISPR\/Cas9 gene editing therapy","volume":"4","author":"Young","year":"2017","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0505","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1021\/acssynbio.0c00325","article-title":"Developing methods to circumvent the conundrum of chromosomal rearrangements occurring in multiplex gene edition","volume":"9","author":"Borsenberger","year":"2020","journal-title":"ACS Synth Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0510","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","article-title":"Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9","volume":"4","author":"Li","year":"2015","journal-title":"Stem Cell Rep"},{"issue":"418","key":"10.1016\/bs.pmbts.2021.01.029_bb0515","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8081","article-title":"Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy","volume":"9","author":"Amoasii","year":"2017","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0520","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aap9004","article-title":"Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing","volume":"4","author":"Long","year":"2018","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0525","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0530","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1038\/s41467-019-12335-x","article-title":"In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse","volume":"10","author":"Amoasii","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/bs.pmbts.2021.01.029_bb0535","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0540","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ymthe.2020.05.024","article-title":"Correction of three prominent mutations in mouse and human models of Duchenne muscular dystrophy by single-cut genome editing","volume":"28","author":"Min","year":"2020","journal-title":"Mol Ther"},{"issue":"6410","key":"10.1016\/bs.pmbts.2021.01.029_bb0545","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/jpm8040038","article-title":"Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy","volume":"8","author":"Lim","year":"2018","journal-title":"J Pers Med"},{"issue":"6201","key":"10.1016\/bs.pmbts.2021.01.029_bb0555","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0560","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1602814","article-title":"CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice","volume":"3","author":"Zhang","year":"2017","journal-title":"Sci Adv"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0565","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtn.2017.02.007","article-title":"CRISPR\/Cas9-mediated genome editing corrects Dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy","volume":"7","author":"Zhu","year":"2017","journal-title":"Mol Ther\u2013Nucleic Acids"},{"issue":"7747","key":"10.1016\/bs.pmbts.2021.01.029_bb0570","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/d41586-019-00814-6","article-title":"NIH supports call for moratorium on clinical uses of germline gene editing","volume":"567","author":"Wolinetz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0575","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s40778-020-00179-x","article-title":"Responsible translational pathways for germline gene editing?","volume":"6","author":"Cwik","year":"2020","journal-title":"Curr Stem Cell Rep"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0580","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41536-020-0094-3","article-title":"Towards stem cell therapies for skeletal muscle repair","volume":"5","author":"Judson","year":"2020","journal-title":"NPJ Regen Med"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0585","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0590","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-genet-051710-150955","article-title":"Regulation of homologous recombination in eukaryotes","volume":"44","author":"Heyer","year":"2010","journal-title":"Annu Rev Genet"},{"issue":"56","key":"10.1016\/bs.pmbts.2021.01.029_bb0595","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1038\/sj.onc.1210871","article-title":"Non-homologous end-joining, a sticky affair","volume":"26","author":"van Gent","year":"2007","journal-title":"Oncogene"},{"issue":"7631","key":"10.1016\/bs.pmbts.2021.01.029_bb0600","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0605","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2012.04.078","article-title":"Gene therapy for muscular dystrophy: Lessons learned and path forward","volume":"527","author":"Mendell","year":"2012","journal-title":"Neurosci Lett"},{"issue":"15","key":"10.1016\/bs.pmbts.2021.01.029_bb0610","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne's muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2021.01.029_bb0615","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/hum.2006.17.440","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors","volume":"17","author":"Halbert","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1016\/bs.pmbts.2021.01.029_bb0620","first-page":"493","article-title":"Evading the immune response upon in vivo gene therapy with viral vectors","volume":"11","author":"Sack","year":"2009","journal-title":"Curr Opin Mol Ther"},{"issue":"13","key":"10.1016\/bs.pmbts.2021.01.029_bb0625","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0630","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/hum.2016.141","article-title":"Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne muscular dystrophy, Becker muscular dystrophy, inclusion body myositis, or GNE myopathy","volume":"28","author":"Zygmunt","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0635","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1089\/hum.2013.092","article-title":"Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect","volume":"24","author":"Flanigan","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/bs.pmbts.2021.01.029_bb0640","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ymthe.2020.05.007","article-title":"Immunity to Cas9 as an obstacle to persistent genome editing","volume":"28","author":"Gough","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0645","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/bs.pmbts.2021.01.029_bb0650","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0655","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41467-019-09693-x","article-title":"Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes","volume":"10","author":"Ferdosi","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0660","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0665","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.omtm.2020.09.016","article-title":"In vivo gene editing of muscle stem cells with Adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy","volume":"19","author":"Kwon","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"9","key":"10.1016\/bs.pmbts.2021.01.029_bb0670","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ymthe.2019.06.012","article-title":"AAV9 edits muscle stem cells in Normal and dystrophic adult mice","volume":"27","author":"Nance","year":"2019","journal-title":"Mol Ther"},{"issue":"18","key":"10.1016\/bs.pmbts.2021.01.029_bb0675","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0680","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0685","series-title":"GeneReviews","article-title":"X-linked myotubular myopathy","author":"Dowling","year":"1993"},{"key":"10.1016\/bs.pmbts.2021.01.029_bb0690","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther\u2013Nucleic Acids"},{"issue":"1","key":"10.1016\/bs.pmbts.2021.01.029_bb0695","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/bs.pmbts.2021.01.029_bb0700","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/bs.pmbts.2021.01.029_bb0705","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1111\/febs.15466","article-title":"The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene","volume":"287","author":"Hoffman","year":"2020","journal-title":"FEBS J"}],"container-title":["Progress in Molecular Biology and Translational Science","Curing Genetic Diseases Through Genome Reprogramming"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117321000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117321000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T22:06:42Z","timestamp":1717020402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117321000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323853019"],"references-count":140,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2021.01.029","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}